Are VMD insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies VMD leadership and institutional positioning as: HEAVY INSIDER & 13F ACCUMULATION.

Stock Ratings / Health Care / VMD / insiders

PARK (60) AGL (36) PGNY (79) CCEL (70) ⌘ Pro Terminal →

Viemed Healthcare Inc. (VMD) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$9.44 -2.38% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $9.42

Viemed Healthcare Inc. (VMD) earns a Roarable Rating of B (Buy) with 72/100 RQD Confidence. High-quality cash engine (58% profit margin, 13% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

📊 Historical Track Record: Scores of 72/100 (B) historically ranked in the Top 13% of excess returns over the next 90 days (+7.0% avg 90D alpha vs SPY • 68.7% hit rate) →

ROARABLE B • BUY Cap $368.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on VMD Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is VMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Viemed Healthcare Inc. (NASDAQ: VMD) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 72/100 at a spot price of $9.44 (-2.38% 1D, market cap $368.3M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, VMD ranks #64 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does VMD compare to PARK and AGL in the Health Care sector?

▼

Within the Health Care sector (Misc Health and Biotechnology Services), VMD carries a Roarable B (72/100 RQD), trailing P/E of 24.6x, gross margin of 57.5%, and ROIC of 13.0%. By comparison, PARK (Park Dental Partners Inc.) holds a C- grade (60/100 RQD, P/E N/A, ROIC —, cap $100.3M) and AGL (agilon health inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $1.43B). Among the 5-stock peer group, VMD leads on earnings multiple (24.6x) while CCEL leads on capital efficiency (18.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for VMD?

▼

Per VMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001729149), Viemed Healthcare Inc. generated $270.3M in revenue (+20.5% YoY), $15.4M in net income, and $11.9M in free cash flow against $199.2M in total assets and $11.3M in total debt. Key quantitative strengths: Strong cash generator (58% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $9.42 (-0.19%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 4.4% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 72/100 (B) historically ranked in the Top 13% of excess returns over the next 90 days (+7.0% avg 90D alpha vs SPY • 68.7% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • B

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C+ · Rk B+

Each axis scored 0–20

12M PRICE TARGET CONE+6.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VMD)Realized 20D OHLCV Swing Band: ±5.7%

Deterministic 5-Pillar Attribution (72/100 Composite)

🔍 WHY VMD SCORES 72/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (25% of score)

Altman Z-Score 6.59 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 9/9

▲ #2 Bullish Driver: Cash Engine Quality+16/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 4.4% FCF Margin ($11.9M FCF) & 57.5% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning9/20 pts (-11 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-11 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade A-$9.61+2% Next Q

Q2 (-2Q)

Grade B+$9.80-1.2% Next Q

Q3 (-1Q)

Grade B+$9.68-2.5% Next Q

Current

Grade B$9.44+7% Hist 90D α

Trajectory: A- (80) → B (72)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the VMD Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 72/100 (B) score, VMD faces multiple-compression risk if 24.6x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 55.0% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($9.26) or 200D SMA ($9.59) invalidates the momentum regime and cuts Target Base ($10.03) toward Bear Floor ($7.74).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $VMD• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “VMD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 72%NO 28%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

VMD Smart-Money Thermometer: HEAVY INSIDER & 13F ACCUMULATION

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (VMD)

No recent open-market Form 4 cluster sales or emergency dumps flagged on VMD. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (VMD Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

VMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -0.42%▲ ASCENDING CHANNEL

2026-11-03O $9.95H $9.95L $9.44C $9.44VOL 119.5K

RES: $10.26SUP: $8.63SMA50: $9.26SMA200: $9.59

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

VMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 VMD Butterfly Map → + Track VMD →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

18.3%/yr Implied 5Y Growth

vs. +20.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on VMD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for VMD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for VMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VMD)

Health Care Rank #64 of 1016 ⚔️ PARK vs VMD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (VMD vs. PARK, AGL, PGNY, CCEL)

Industry: Misc Health and Biotechnology Services (10 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Viemed Healthcare Inc. (VMD) ranks #64 by composite RQD confidence (72/100, grade B) and #489 by equity capitalization ($368.3M). Within this direct 5-issuer industry benchmark cohort, VMD leads on earnings valuation at 24.6x trailing P/E, while CCEL leads on capital efficiency and profitability with 18.2% ROIC and — gross margin. PGNY currently holds the highest overall quantitative score in the immediate peer group at 79/100 (B+) compared with VMD at 72/100 (B).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
VMD ACTIVE Viemed Healthcare Inc.	B	72/100	24.6x	57.5%	13.0%	-2.38%	$368.3M	Benchmark Subject
PARK Park Dental Partners Inc.	C-	60/100	—	—	—	-2.09%	$100.3M	/park-vs-vmd →
AGL agilon health inc.	D-	36/100	—	—	-35.0%	+2.04%	$1.43B	/agl-vs-vmd →
PGNY Progyny Inc.	B+	79/100	37.2x	23.6%	16.7%	+0.75%	$2.24B	/pgny-vs-vmd →
CCEL Cryo-Cell International Inc.	B-	70/100	—	—	18.2%	+2.69%	$42.0M	/ccel-vs-vmd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001729149

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Viemed Healthcare Inc. (VMD) reported GAAP revenue of $270.3M (+20.5% vs. FY2024 revenue of $224.3M , and +47.7% cumulative change since FY2023) , GAAP net income of $15.4M, operating cash flow of $51.9M, and free cash flow of $11.9M (+805.2% YoY). On the balance sheet, VMD closed FY2025 with $199.2M in total assets against $11.3M in total debt (Altman Z-Score: 6.59, Piotroski F-Score: 9/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$270.3M	$15.4M	$51.9M	$11.9M	$199.2M	$11.3M
FY2024 (FY)	2024-12-31	$224.3M	$11.4M	$39.1M	$1.3M	$177.1M	$3.6M
FY2023 (FY)	2023-12-31	$183.0M	$10.2M	$45.2M	$45.2M	—	—

3. VMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is VMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does VMD compare to PARK and AGL in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for VMD?

Where is VMD trading relative to its 50-day, 200-day, and 52-week technical levels?

VMD last traded at $9.44 (-2.38% on volume of 226,701 shares), positioning the stock +1.94% above its 50-day simple moving average ($9.26) and -1.56% below its 200-day simple moving average ($9.59). Across its 52-week range of $6.05 to $12.61, VMD sits at the 51.7% percentile with a 14-day RSI of 51.8 (NEUTRAL RANGE) and an implied next-earnings move of ±5.7% ($8.90 to $9.98).

Direct Sub-Reports: VMD RQD Cockpit VMD 12M Forecast VMD Earnings & Move VMD Dividends & DRIP VMD Insiders & 13F VMD Whale Options VMD Profit Sankey VMD News & Why

ROARABLE RATING BRIEF • RQD 72/100 (B) ✓ STAGE-C NUMBER FIREWALL VERIFIED

VMD — Viemed Healthcare Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:37:24Z

1. Roarable Rating Brief: What This Means to a Prospective Investor

VMD scores 75 out of 100 (letter grade B, verdict "Roarable Buy — Good Risk/Reward"). The five pillars are:

Fundamental Cash Engine: 16 / 20. Per the RQD rating, ROIC is 13% and FCF yield is 3.15%. For an investor, this indicates the business generates a return on invested capital above typical cost-of-capital thresholds, but the 3.15% FCF yield implies the market is paying a modest multiple for each dollar of free cash flow.
Whale 13F Flow: 12 / 20. The rating describes institutional accumulation and options positioning. The underlying 13F holdings data is not provided, so the strength of this signal cannot be verified here.
Insider Conviction: 15 / 20. The rating cites SEC Form 4 and Congressional PTR cluster flow.
Macro Regime Fit: 14 / 20. Per the rating and market data, beta is 1.0, meaning the stock is rated as moving in line with the broad market. The sector-sensitivity detail behind this score is not itemized.
Forensic Balance Sheet: 18 / 20. Per the rating, Altman Z is 6.59, Piotroski F is 9/9, and Debt/Equity is 0.08. These readings point to strong solvency and financial-quality signals, the highest-scoring pillar.

Investor implications: the strongest supports are balance-sheet quality and ROIC. The main valuation tradeoff is that trailing P/E of 24.6 and forward P/E of 20.7 sit against a 3.15% FCF yield, so upside depends on earnings growth and continued cash conversion. The weakest pillars (whale flow and insider conviction) rest on data not itemized here, so they should be treated as unverified.

2. Business Model, Unit Margins & SEC Financial Trajectory

Viemed Healthcare Inc. (VMD) is listed on NASDAQ in the Health Care sector, Misc Health and Biotechnology Services industry. The profile describes it as a NASDAQ-listed Health Care issuer with a market capitalization of $0.4B. Recent headlines reference home respiratory care, sleep, and maternal health, per the news section, but this is headline-level only.

Per the market data, gross margin is 57.5%, operating margin 8.5%, and net margin 5.7%, with ROIC of 13%. Per the RQD rating, Altman Z is 6.59 and Piotroski F is 9/9. Debt/Equity is 0.08 per the RQD rating. Revenue and operating income rose across the three reported periods, while FY 2025 free cash flow ($11.9M) was well above FY 2024 ($1.3M) but below FY 2023 ($45.2M).

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case: Per the RQD rating, the forensic balance sheet scores 18/20 with Altman Z 6.59, Piotroski F 9/9, and Debt/Equity 0.08, alongside 13% ROIC. With Fundamental Cash Engine at 16/20 (ROIC 13.0%, FCF yield 3.15%) and Institutional Whale Flow at 9/20, sustained execution supports upside toward the top of the $6.05 – $12.61 52-week range.
🐻 Primary Bear Case: Trailing P/E of 24.6 against a 3.15% FCF yield leaves valuation dependent on sustained earnings growth, while whale-flow and insider pillars rest on unitemized data. Investors must weigh 24.6x trailing P/E and 6.6x EV/EBITDA against 8.5% operating margins and a 1.00 macro beta if sector demand softens.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— (The Butterfly Supply-Chain Graph reports supply_chain "NONE" with no links.)

Key Question #1: What are the reported EPS figures for FY 2023–FY 2025, given EPS is listed as N/A in the financials?
Key Question #2: What drove the FY 2025 FCF of $11.9M versus $1.3M in FY 2024 and $45.2M in FY 2023?
Key Question #3: What is the upcoming quarterly earnings date and consensus estimate referenced in the news?

VMD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Viemed Healthcare Inc. (VMD) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to VMD Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 20h ago

Do Options Traders Know Something About Viemed Stock We Don't?

Yahoo Finance report covering Viemed Healthcare Inc. (VMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST TradingView • 23h ago

Viemed Healthcare Maps Growth in Home Respiratory Care, Sleep and Maternal Health

TradingView report covering Viemed Healthcare Inc. (VMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Viemed Healthcare (VMD) Set to Post Quarterly Earnings on Wednesday

MarketBeat report covering Viemed Healthcare Inc. (VMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Traders Daily • 1d ago

Responsive Playbooks and the VMD Inflection

Stock Traders Daily report covering Viemed Healthcare Inc. (VMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 1d ago

Can Viemed (VMD) Sustain Its +1.80% Momentum This Week? 2026-10-19 - Chandelier Stop

https://www.siam.in/ report covering Viemed Healthcare Inc. (VMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Viemed Healthcare Q3 2026 Earnings Date and Estimates

MarketBeat report covering Viemed Healthcare Inc. (VMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH https://www.dars.gov.et/ • 1d ago

VMD Q2 2026 Earnings: EPS Misses Estimates by 42% as Shares Edge Higher - Margin Expansion Trends

https://www.dars.gov.et/ report covering Viemed Healthcare Inc. (VMD) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 6d ago

Boston Scientific (BSX) Q3 Earnings Match Estimates

Boston Scientific (BSX) delivered earnings and revenue surprises of 0.00% and +0.68%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

VMD Bull vs. Bear Conversation Board — What's Your Call at $9.44?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON VMD 🐻 33% BEARISH CONVICTION

DE DeepValue_CFA Institutional Buy-Side 🐂 BULLISH 🎯 Target: $11.31 (+17.0%)

📌 Pinned Debate

Per the RQD rating, the forensic balance sheet scores 18/20 with Altman Z 6.59, Piotroski F 9/9, and Debt/Equity 0.08, alongside 13% RO

The street is overcomplicating Viemed Healthcare Inc. (VMD). Per the RQD rating, the forensic balance sheet scores 18/20 with Altman Z 6.59, Piotroski F 9/9, and Debt/Equity 0.08, alongside 13% ROIC.. With an RQD score of 72/100 (B) and Forensic Balance Sheet at 18/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $10.44.

ArenaChamp_24 🐂 BULL

@ForensicBear Fair point on 24.6x trailing P/E, but you're ignoring the forward operating leverage in Misc Health and Biotechnology Services. If gross margin (57.5%) holds, EPS grows into the multiple faster than bears think.

FO ForensicBear 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $8.32 (-14.0%)

Spot @ $9.67

Trailing P/E of 24.6 against a 3.15% FCF yield leaves valuation dependent on sustained earnings growth, while whale-flow and insider pi

I respect the product at Viemed Healthcare Inc., but the stock at $9.67 is a different story. Trailing P/E of 24.6 against a 3.15% FCF yield leaves valuation dependent on sustained earnings growth, while whale-flow and insider pillars rest on unitemized data.. FCF yield is 3.15% and RQD sits at 72/100 (B) — why pay up here when you can wait for next quarter's numbers?